NCT05927415
A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod
A Phase 1, Open-label, Study to Evaluate the Pharmacokinetics of Efgartigimod IV 10 mg/kg Single Dose Administered in Participants With Renal Impairment
argenx·Phase 1·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Renal Impairment
- Drug/Device/Intervention
- Efgartigimod IV
- Study type
- Interventional
- Intervention type
- biological
Sponsor & location
- Primary sponsor
- argenx
Timeline & enrollment
- Phase
- Phase 1
- Start date
- Jul 10, 2023
- End date
- Jul 01, 2024
- Enrollment
- 48 participants
Primary outcome
Efgartigimod PK parameters (Cmax)
Summary
A study to test how kidney problems influence the blood concentrations of efgartigimod
ICD-10 classifications
Renal failureDisorders resulting from impaired renal tubular functionDisorder resulting from impaired renal tubular function, unspecifiedOther disorders resulting from impaired renal tubular functionAcute renal failure
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05927415
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05927415 through Pure Global AI's free database. This Phase 1 trial is sponsored by argenx and is currently Not yet recruiting. The study focuses on Renal Impairment. Target enrollment is 48 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.